On June 10, 2020 Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, reported that Jounce management will participate in a fireside chat at the Raymond James Human Health Innovation Conference on Wednesday, June 17, 2020 at 3:00 p.m. ET (Press release, Jounce Therapeutics, JUN 10, 2020, View Source [SID1234560964]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available by visiting "Events and Presentations" in the Investors and Media section of Jounce’s website at www.jouncetx.com. A replay of the webcast will be archived for 30 days following the presentation.

On June 10, 2020 PharmAbcine Inc. (KOSDAQ: 208340ks) reported that it has entered into a strategic partnership with Thermo Fisher Scientific for the development and manufacturing of PMC-309, a next-generation immune checkpoint blockade to treat cancer (Press release, PharmAbcine, JUN 10, 2020, View Source [SID1234560982]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under this agreement, PharmAbcine will take advantage of Thermo Fisher’s Quick to Clinic integrated service offering, a program that accelerates drug development for IND submission for Phase I.

PMC-309 is a novel fully human monoclonal IgG targeting unique epitope of human VISTA (V-domain Ig suppressor of T cell activation) primarily expressed on MDSC (myeloid-derived suppressor cells). It can provide a promising immunotherapeutic strategy to improve the antitumor activity through inhibition of VISTA-positive immunosuppressive cell activities.

"Due to the limitation of response rate and drug resistance of all marketed PD1/PDL1 targeting immuno oncology drugs, next generation immuno oncology drug with new modality is desperately needed," said Dr. Jin-San Yoo, CEO of PharmAbcine. "We are excited about the progress we have made with PMC-309 and strongly believe that PMC-309 will fulfill the gap in immuno oncology drug landscape."

The drug product of PMC-309 for clinical trial will be developed at Thermo Fisher’s Princeton, NJ, USA and the Brisbane’s site in Australia will facilitate for the drug substances. PharmAbcine is planning to initiate IND enabling studies this year and submit global IND in 2021.

On June 10, 2020 Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company in Clean Health and Beauty markets through its consumer brands and a top supplier of sustainable and natural ingredients, reported the closing of its previously announced private investment in public equity (PIPE) in the Company (Press release, Amyris Biotechnologies, JUN 10, 2020, View Source [SID1234560984]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Amyris received total gross proceeds of $200 million, before deducting placement agent fees and offering expenses.

The investment was made by a consortium of high quality institutional and accredited investors and mutual funds with expertise in health care, biotechnology or a consumer orientation consisting of approximately 70% new investors and 30% existing investors. The Company expects to use the proceeds from the offering for general corporate purposes and to repay certain outstanding indebtedness.

Jefferies LLC and Cowen and Company, LLC served as joint lead placement agents for the financing. Oppenheimer & Co. Inc. served as co-placement agent.

Separately, H.C. Wainwright & Co. provided advisory services to the Company.

The securities sold in the private placement have not been registered under the Securities Act of 1933, as amended, or any state or other applicable jurisdiction’s securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state or other jurisdictions’ securities laws. The Company has agreed to file a registration statement with the U.S. Securities and Exchange Commission (the "SEC") registering the resale of the shares of common stock sold in the private placement and the shares of common stock issuable upon exercise of the preferred stock.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Additional details regarding the private placement are included in a Form 8-K filed with the Securities and Exchange Commission on June 4, 2020.

On June 10, 2020 Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, reported that the Company will participate in an upcoming virtual investor conference. Jigar Raythatha, CEO, will present at the Goldman Sachs 41st Annual Global Healthcare Conference at 8:00 AM EDT on June 11 (Press release, Constellation Pharmaceuticals, JUN 10, 2020, View Source [SID1234560967]). A live audio webcast of Mr. Raythatha’s presentation and archives for replay will be available on the Investor Relations section of Constellation’s website at View Source The audio webcast replay will be available for 30 days following the live presentation.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On June 10, 2020 Adagene Incorporated, a precision antibody engineering, discovery and development company, and Tanabe Research Laboratories U.S.A., Inc. (TRL), a subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC), reported that the companies have entered into a strategic collaboration under which TRL will use Adagene’s SAFEbody technology platform to generate a masked antibody in combination with the cytotoxic payload technologies used at TRL, for the development of an ADC against a solid tumor target (Press release, Adagene, JUN 10, 2020, View Source [SID1234560985]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Adagene has developed the SAFEbody technology platform for discovery of a masked antibody which is activated by factors present in tumor tissues but not in healthy tissues. This allows for the tumor-specific targeting of antibodies with minimized on-target toxicity in healthy tissues. The tumor-specific targeting technology is expected to safely enhance the therapeutic index of the ADC delivery of the cytotoxic payload.

"We look forward to combining our SAFEbody technology with TRL’s ADC technologies to develop a treatment for a solid tumor target," said Peter Luo, Chief Executive Officer and Co-Founder of Adagene. "Adagene’s precision protein engineering capabilities enable us to create highly masked antibodies while retaining their efficacy. Traditional ADC technologies are limited in most solid tumor targets because toxicity was observed at optimal efficacious doses. Our new modality, POWERbody, combining SAFEbody with ADCs, aims to deliver safe and potent therapies toward a wide range of targets."

Financial terms and target identification were not disclosed.